Evaluation of carboxymethyl-β-cyclodextrin with acid function: Improvement of chemical stability, oral bioavailability and bitter taste of famotidine

International Journal of Pharmaceutics

Volumn 397, Issue 1-2, 2010, Pages 1-8

  Mady, Fatma M ^a,b   Abou Taleb, Ahmed E ^c   Khaled, Khaled A ^a   Yamasaki, Keishi ^d   Iohara, Daisuke ^d   Taguchi, Kazuaki ^b   Anraku, Makoto ^e   Hirayama, Fumitoshi ^d   Uekama, Kaneto ^d   Otagiri, Masaki ^b,d  

^a Minia University   (Egypt)

^b KUMAMOTO UNIVERSITY   (Japan)

^c Assiut University   (Egypt)

^d SOJO UNIVERSITY   (Japan)

^e FUKUYAMA UNIVERSITY   (Japan)

Author keywords

Carboxymethyl CyD; Chemical stability; Famotidine; Masking the bitter taste and oral disintegrating tablets; Oral bioavailability

Indexed keywords

BETA CYCLODEXTRIN SULFOBUTYL ETHER; CARBOXYMETHYL BETA CYCLODEXTRIN; FAMOTIDINE;

ACIDITY; ADULT; ANIMAL EXPERIMENT; AQUEOUS SOLUTION; AREA UNDER THE CURVE; ARTICLE; BITTER TASTE; CARBON NUCLEAR MAGNETIC RESONANCE; CATALYSIS; CHEMICAL INTERACTION; CLINICAL TRIAL; COMPLEX FORMATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DEGRADATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG STABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; HYDROLYSIS; MALE; MASKING; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAT; SINGLE BLIND PROCEDURE; TABLET DISINTEGRATION; TABLET DISINTEGRATION TIME; TABLET FORMULATION; THERMODYNAMICS; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADULT; ANIMALS; ANTI-ULCER AGENTS; AREA UNDER CURVE; BETA-CYCLODEXTRINS; BIOLOGICAL AVAILABILITY; DRUG STABILITY; FAMOTIDINE; FEMALE; HALF-LIFE; HUMANS; INTESTINAL ABSORPTION; MALE; RATS; RATS, WISTAR; SOLUBILITY; TABLETS; TASTE; YOUNG ADULT;

EID: 77955982135     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.06.018     Document Type: Article

References (37)

1. Adachi H., Irie T., Hirayam F., Uekam K. Stabilization of prostaglandin E1 in fatty alcohol propylene glycol ointment by acidic cyclodextrins derivatives O-carboxymethyl-O-ethyl-bcyclodextrins. Chem. Pharm. Bull. 1992, 40:1586-1591.
2. 15N NMR spectra of famotidine. J. Mol. Struct. 2001, 563-564(1-3):347-351.
3. Carrier R.L., Miller L.A., Ahmed I. The utility of cyclodextrins for enhancing oral bioavailability. J. Contr. Rel. 2007, 123:78-99.
4. Connors K.A. The stability of cyclodextrin complexes in solution. Chem. Rev. 1997, 97:1325-1357.
5. Dollery C. Therapeutic drugs 1999, Churchill Livingstone, Longman group, Edinburgh, pp. F14-F18. second ed.
6. 1H NMR. J. Pharm. Biomed. Anal. 2002, 29:487-494.
7. Elkheshen S.A., Ahmed S.M., Al-Quadeib B.T. Inclusion complexes of piroxicam with b-cyclodextrin derivatives in comparison with the natural β-cyclodextrin. Pharm. Ind. 2002, 64:708-715.
8. Fu Y., Yang S., Jeong S.H., Kimura S., Park K. Orally fast disintegrating tablets: developments, technologies, taste masking and clinical studies. Crit. Rev. Ther. Drug Carrier Syst. 2004, 21:433-476.
9. Fukami J., Ozawa A., Yoshihashi Y., Yonemochi E., Terada K. Development of fast disintegrating compressed tablets using amino acid as disintegration accelerator: evaluation of wetting and disintegration of tablet on the basis of surface free energy. Chem. Pharm. Bull. 2005, 53:1536-1539.
10. Guvener B., Ates S. The stability study on famotidine in simulated gastric medium by HPLC. International Pharmaceutical Technology Symposium 1988, 54. (abstract).
11. Higuchi T., Connors K.A. Phase solubility techniques. Adv. Anal. Chem. Instrum. 1965, 4:117-118.
12. Hirayama F., Uekama K. Method of investigating and preparing inclusion compounds. Cyclodextrins and their industrial uses 1987, 133-172. Edition de Sante, Paris. D. Duchene (Ed.).
13. Islam M.S., Narurkar M.M. The effect of 2-hydroxypropyl β-cyclodextrin on the solubility, stability and dissolution rate of famotidine. Drug Dev. Ind. Pharm. 1991, 17:1229-1239.
14. Jarho P., Urtti A., Jarvinen T. Hydroxypropyl β-cyclodextrin increases the aqueous solubility and stability of pilocarpine prodrug. Pharm. Res. 1995, 9:1371-1375.
15. Jarho P., Velde D.V., Stella V.J. Cyclodextrin-catalyzed deacetylation of spironolactone is pH and cyclodextrin dependent. J. Pharm. Sci. 2000, 89:241-249.
16. Junnarkar G.H., Stavchansky S. Isothermal and nonisothermal decomposition of famotidine in aqueous solution. Pharm. Res. 1995, 12:599-604.
17. Khan S., Kataria P., Nakhat P., Yeole P. Taste masking of ondansetron hydrochloride by polymer carrier system and formulation of rapidly disintegration tablets. AAPS PharmSci.Tech. 2007, 8:E1-E7. (article 46).
18. Kikuchi M., Hirayama F., Uekama K. Improvement of oral and rectal bioavailabilities of carmofur by methylated β-cyclodextrin complexations. Int. J. Pharm. 1987, 38:191-198.
19. Kimura K., Hirayama F., Arima H., Uekama K. Solid-state 13C nuclear magnetic resonance spectroscopic study on amorphous solid complexes of tolbutamide with 2-hydroxypropyl-α-and β-cyclodextrins. Pharm. Res. 1999, 16:1729-1734.
20. Loftsson T., Brewster M.E. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J. Pharm. Sci. 1996, 85:1017-1025.
21. Loftsson T., Fridriksdottir H., Gudmundsdottir T.K. The effect of water soluble polymers on aqueous solubility of drugs. Int. J. Pharm. 1996, 127:293-296.
22. Loftsson T., Fridriksdottir H., Sigurdadottir A.M., Ueda H. The effect of water soluble polymers on drug-cyclodextrin complexation. Int. J. Pharm. 1994, 110:169-177.
23. Mady, F.M., Abou-Taleb, A.E., Khaled, K.A., Yamazaki, K., Ishiguro, T., Iohara, D., Hirayama, F., Uekama, K., Otagiri, M., 2010. Enhancement of the aqueous solubility and masking the bitter taste of famotidine using SBE-β-CyD complexation approach. J. Pharm. Sci. (epub 12 April 2010).
24. Mallick S., Mondal A., Sannigrahi S. Kinetic measurements of the hydrolytic degradation of cefixime: effect of Captisol complexation and water-soluble polymers. J. Pharma. Pharmacol. 2008, 60:833-841.
25. Mallick S., Pattnaik S., Swain K., De P.K., Mondal A., Ghoshal G., Saha A. Interaction characteristics and thermodynamic behavior of gatifloxacin by aluminium hydroxide. Drug Dev. Ind. Pharm. 2007, 33:535-541.
26. Mosher G.L., Thompson D.O. Encyclopedia of pharmaceutical technology 2002, Marcel Dekker. second ed. J. Swarbrick (Ed.).
27. Mou-ying F.L., Saul B., Linda W., Ping L., Diesner C., Hernandez L., Vadnere M.A. Polymeric carrier system for taste masking of macrolide antibiotics. Pharm. Res. 1991, 8:706-712.
28. Okimoto K., Rajewski R.A., Uekama K., Jona J.A., Stella V.J. The interaction of charged and uncharged drugs with neutral (HP-β-CyD) and anionic (SBE7-β-CyD) β-cyclodextrin. Pharm. Res. 1996, 13:256-264.
29. Savolainen J., Jarvinen K., Taipale H., Jarho P., Loftsson T., Jarvinen T. Coadministration of a water-soluble polymer increases the usefulness of cyclodextrins in solid oral dosage forms. Pharm. Res. 1998, 15:1696-1701.
30. Schiermeier S., Schmidt P. Fast dispersible ibuprofen tablets. Eur. J. Pharm. Sci. 2002, 15:259-305.
31. Suleiman M.S., Najib N.M., Hassan M.A., Abdel-Hamid M.E. Kinetics of the acid-catalyzed hydrolysis of famotidine. Int. J. Pharm. 1989, 54:65-69.
32. Valero M., Perez-Revuelta B.I., Rodriguez L.J. Effect of PVP K-25 on the formation of the naproxen:β-cyclodextrin complex. Int. J. Pharm. 2003, 253:97-110.
33. Watanabe Y., Ishikawa T., Mukai B., Shiraishi S., Utoguchi N., Fujii M., et al. New compressed tablet rapidly disintegrating in saliva in the mouth using crystalline cellulose and a disintegrant. Biol. Pharm. Bull. 1995, 18:1308-1310.
34. Wong J.W., Yuen K.H. Improved oral bioavailability of artemisinin through inclusion complexation with β- and γ-cyclodextrin. Int. J. Pharm. 2001, 227:177-185.
35. Yamaoka K., Tanigawara Y., Nakagawa T., Uno T. A pharmacokinetic analysis program (multi) for microcomputer. J. Pharmacobiodyn. 1981, 4:879-885.
36. Yanagisawa I., Hirata Y., Ishii Y. Studies on histamine H receptor antagonists. 2. Synthesis and pharmacological activities of N-sulfamoyl and N-sulfonyl amidine derivatives. J. Med. Chem. 1987, 30:1787-1793.
37. Zarghi A., Shafaati A., Foroutan S.M., Khoddam A. Development of a rapid HPLC method for determination of famotidine in human plasma using a monolithic column. J. Pharm. Biomed. Anal. 2005, 39(3-4):677-680.